Risk of venous thromboembolism in relatives of symptomatic probands with thrombophilia: a systematic review
Nicole J. Langlois
1
Departments of Medicine, University of Ottawa, Ontario, Canada
,
Philip S. Wells
1
Departments of Medicine, University of Ottawa, Ontario, Canada
1
Departments of Medicine, University of Ottawa, Ontario, Canada
1
Departments of Medicine, University of Ottawa, Ontario, Canada
› InstitutsangabenFinancial support: Dr. Wells is a Canada Research Chair. N. Langlois is funded through a Premier’s Research Excellence Award, granted to Dr. Wells.
Clinical equipoise exists regarding whether relatives of individuals with venous thromboembolism (VTE) and thrombophilia should be screened for thrombophilia. There have been no systematic attempts to summarize studies that have assessed the incidence of VTE in relatives. The purpose of this review was to systematically identify and review observational studies with thrombophilic relatives and to summarize their findings with respect to their risk of VTE.
We conducted a systematic literature review and included nine observational studies meeting a priori inclusion criteria. Potentially eligible studies evaluated VTE incidence in relatives of index patients (probands) with symptomatic thrombophilia. In the four prospective studies, the incidence of VTE for asymptomatic family members with factor V Leiden ranged from 0.58-0.67% per year, 1.0-2.5% for protein C deficiency, 0.7-2.2% for protein S deficiency, and 4% for antithrombin deficiency. About half of all VTEs occurred during well-known risk periods but incidence rates were decreased by use of prophylaxis. No deaths from pulmonary embolism or fatal hemorrhages from anticoagulants were reported. The incidence of VTE was generally lower in the retrospective studies. The pooled relative risk from four retrospective studies for factor V Leiden carriers was 3.69 (CI 2.27, 6.00) and from two studies the pooled relative risk for deficiencies of protein C, protein S, and antithrombin was 10.58 (CI 5.38, 20.81).
In conclusion, the risk of VTE events in asymptomatic relatives is low, but this may be an underestimate. Anticoagulant prophylaxis during risk periods appears to be of benefit but further research in this area is required.
4
Brenner B,
Sarig G,
Weiner Z.
et al. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause. Thromb Haemost 1999; 82: 6-9.
5
Gris J-C,
Quere I,
Monpeyroux F.
et al. Case-control study of the frequency of thrombophilic disorders in couples with late foetal loss and no thrombotic antecendent. Thromb Haemost 1999; 81: 891-9.
23
Stroup DF,
Berlin JA,
Morton SC.
et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283 (15) 2008-12.
25
Middeldorp S,
Meinardi JR,
Koopman MMW.
et al. A prospective study of asymptomatic carriers of the factor V leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med 2001; 135 (05) 322-7.
26
Simioni P,
Tormene D,
Prandoni P.
et al. Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a prospective cohort study. Blood 2002; 99 (06) 1938-42.
27
Pabinger I,
Kyrle PA,
Heistinger M.
et al. The risk of thromboembolism in asymptomatic patients with Protein C and Protein S deficiency: a prospective cohort study. Thromb Haemost 1994; 71 (04) 441-5.
28
Sanson BJ,
Simioni P,
Tormene D.
et al. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of an-tithrombin, Protein C or Protein S: A prospective cohort study. Blood 1999; 94 (11) 3702-6.
29
Simioni P,
Sanson BJ,
Prandoni P.
et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81 (02) 198-202.
30
Bucciarelli P,
Rosendaal FR,
Tripodi A.
et al. Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. Arterioscler Thromb Vasc Biol 1999; 19 (04) 1026-33.
31
Faioni EM,
Franchi F,
Bucciarelli P.
et al. Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor V R506Q (factor V Leiden). Blood 1999; 94 (09) 3062-6.
32
Lensen R,
Bertina RM,
Vandenbroucke JP.
et al. High factor VIII levels contribute to the thrombotic risk in families with factor V Lei-den. Br J Haematol 2001; 114 (02) 380-6.
33
Middeldorp S,
Koopman MMW,
van Pampus ECM.
et al. The incidence of venous thromboembolism in family members of patients with Factor V Leiden mutation and venous thrombosis. Ann Intern Med 1998; 128 (01) 15-20.
34
Castaman G,
Tosetto A,
Ruggeri M.
et al. Pseudohomozygosity for activated protein C resistance is a risk factor for venous thrombosis. Br J Haematol 1999; 106 (01) 232-6.
35
Koeleman BP,
Reitsma PH,
Allaart CF.
et al. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84 (04) 1031-5.
36
Koeleman BP,
van Rumpt D,
Hamulyak K.
et al. Factor V Leiden: an additional risk factor for thrombosis in protein S deficient families?. Thromb Haemost 1995; 74 (02) 580-3.
38
Rintelen C,
Pabinger I,
Bettelheim P.
et al. Impact of the factor II: G20210A variant on the risk of venous thromboembolism in relatives from families with the factor V: R506Q mutation. Eur J Haematol 2001; 67 (03) 165-9.
39
Schambeck CM,
Hinney K,
Haubitz I.
et al. Familial clustering of high factor VIII levels in patients with venous thromboembolism. Arterioscler Thromb Vasc Biol 2001; 21 (02) 289-92.
40
van Boven HH,
Vandenbroucke JP,
Briet E.
et al. Gene-gene and gene-environment interactions determine risk of thrombosis in families with inherited antithrombin deficiency. Blood 1999; 94 (08) 2590-4.
41
Castaman G,
Tosetto A,
Simioni M.
et al. Phenotypic APC resistance in carriers of the A20210 prothrombin mutation is associated with an increased risk of venous thrombosis. Thromb Haemost 2001; 86 (03) 804-8.
42
Lensen RPM,
Bertina RM,
deRonde H,
Van-denbroucke JP,
Rosendaal FR.
Venous thrombotic risk in family members of unselected individuals with Factor V Leiden. Thromb Haemost 2000; 83 (06) 817-21.
43
Martinelli I,
Mannucci PM,
De Stefano V.
et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: A study of 150 families. Blood 1998; 92 (07) 2353-8.
44
Martinelli I,
Legnani C,
Bucciarelli P,
Grandone E,
De Stefano V,
Mannucci PM.
Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. Thromb Haemost 2001; 86 (03) 800-3.
45
Martinelli I,
Bucciarelli P,
Margaglione M.
et al. The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. Br J Haematol 2000; 111 (04) 1223-9.
46
Allaart CF,
Poort SR,
Rosendaal FR.
et al. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet 1993; 341 8838 134-8.
47
Makris M,
Leach M,
Beauchamp NJ.
et al. Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis, in families with inherited deficiencies of protein S. Blood 2000; 95 (06) 1935-41.
48
Pabinger I,
Schneider B.
Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose-und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Arterioscler Thromb Vasc Biol 1996; 16 (06) 742-8.
49
Mateo J,
Oliver A,
Borrell M.
et al. Increased risk of venous thrombosis in carriers of natural anticoagulant deficiencies. Results of the family studies of the Spanish Multicenter Study on Thrombophilia (EMET study). Blood Coagul Fibrinolysis 1998; 9 (01) 71-8.
50
van Boven HH,
Reitsma PH,
Rosendaal FR.
et al. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost 1996; 75 (03) 417-21.
51
De Stefano V,
Leone G,
Mastrangelo S.
et al. Clinical manifestations and management of inherited thrombophilia: retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost 1994; 72 (03) 352-8.
52
Zoller P,
Svensson PJ,
He X.
et al. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-4.
53
Tirado I,
Mateo J,
Soria JM.
et al. Contribution of prothrombin 20210A allele and factor V Lei-den mutation to thrombosis risk in thrombophilic families with other hemostatic deficiencies. Haematologica 2001; 86 (11) 1200-8.
54
Santamaria A,
Mateo J,
Oliver A.
et al. Risk of thrombosis associated with oral contraceptives of women from 97 families with inherited thrombophilia: high risk of thrombosis in carriers of the G20210A mutation of the pro-thrombin gene. Haematologica 2001; 86 (09) 965-71.
55
Kosch A,
Junker R,
Kurnik K.
et al. Prothrombotic risk factors in children with spontaneous venous thrombosis and their asymptomatic parents: a family study. Thromb Res 2000; 99 (06) 531-7.
56
Pabinger I,
Schneider B.
Thrombotic risk of women with hereditary antithrombin III-, protein C-and protein S-deficiency taking oral contraceptive medication. The GTH Study Group on Natural Inhibitors. Thromb Haemost 1994; 71 (05) 548-52.
57
Simioni P,
Prandoni P,
Girolami A.
Low rate of venous thromboembolism in asymptomatic relatives of probands with factor V Leiden mutation. Ann Intern Med 1999; 130 (06) 538
58
Franco RF,
Middeldorp S,
Meinardi JR.
et al. Factor XIII Val34Leu and the risk of venous thromboembolism in factor V Leiden carriers. Br J Haematol 2000; 111 (01) 118-21.
59
Orwin RG.
Evaluating coding decisions. In: The handbook of research synthesis.
Cooper H,
Hedges LV.
editors New York:: Russell Sage Foundation; 1994: 140-60.
60
Tormene D,
Simioni P,
Prandoni P.
et al. The incidence of venous thromboembolism in thrombophilic children: a prospective cohort study. Blood 2002; 100 (07) 2403-5.
